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Abstract
Inactivation of all utrophin isoforms in dystrophin-deficient mdx mice results in a strain of utrophin knockout mdx (uko/
mdx) mice. Uko/mdx mice display severe clinical symptoms and die prematurely as in Duchenne muscular dystrophy (DMD)
patients. Here we tested the hypothesis that marginal level dystrophin expression may improve the clinical outcome of uko/
mdx mice. It is well established that mdx3cv (3cv) mice express a near-full length dystrophin protein at ,5% of the normal
level. We crossed utrophin-null mutation to the 3cv background. The resulting uko/3cv mice expressed the same level of
dystrophin as 3cv mice but utrophin expression was completely eliminated. Surprisingly, uko/3cv mice showed a much
milder phenotype. Compared to uko/mdx mice, uko/3cv mice had significantly higher body weight and stronger specific
muscle force. Most importantly, uko/3cv outlived uko/mdx mice by several folds. Our results suggest that a threshold level
dystrophin expression may provide vital clinical support in a severely affected DMD mouse model. This finding may hold
clinical implications in developing novel DMD therapies.
Citation: Li D, Yue Y, Duan D (2010) Marginal Level Dystrophin Expression Improves Clinical Outcome in a Strain of Dystrophin/Utrophin Double Knockout
Mice. PLoS ONE 5(12): e15286. doi:10.1371/journal.pone.0015286
Editor: Ted M. Dawson, Johns Hopkins, United States of America
Received August 6, 2010; Accepted November 4, 2010; Published December 20, 2010
Copyright:  2010 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health (AR-49419, DD) and the Muscular Dystrophy Association (DD). The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: duand@missouri.edu
Introduction
Duchenne muscular dystrophy (DMD) is a prevalent lethal muscle
disease caused by dystrophin gene mutation [1]. Affected boys often
fail to reach development milestones that are related to muscle
function (such as crawling and walking). Most patients are wheelchair-
bound at early teenage and die prematurely in early adulthood.
Restoring dystrophin expression may lead to a cure. However, it is a
technically rather daunting, if not impossible, task to recover
dystrophin expression to the wild type level in every muscle in the
body. For this reason, it is important to determine whether a marginal
level expression can improve life quality and prolong lifespan.
In sharp contrast to human patients, dystrophin-deficient mdx
mice display very mild symptoms. Despite clear histological
evidence of muscle damage, young adult mdx mice do not show
muscle wasting and they maintain a close-to-normal daily activity.
Further, the lifespan of mdx mice is only moderately reduced
[2,3]. One mechanism underlying reduced clinical presentation of
mdx mice is the up-regulation of utrophin, a ubiquitously
expressed dystrophin paralogue. Crossing mdx mice to the
utrophin-null background results in utrophin knockout mdx
(uko/mdx) mice. These double deficient mice present severe
clinical manifestations of muscular dystrophy [4,5]. They show
growth delay, muscle wasting, reduced mobility and a significantly
shortened lifespan [2,4,5,6].
Mdx3cv (3cv) mice carry a point mutation that abolishes all wild
type dystrophin transcripts (Figure S1) [7]. Interestingly, it results
in an exon 65/66 truncated transcript (Figure S1) [7]. This
alternative transcript translates into a near-full-length dystrophin
protein at approximately 5% of the normal level [7,8]. Transgenic
study suggests that exon 65/66-deleted dystrophin is localized at
the sarcolemma and it is capable of restoring syntrophin
expression. Nevertheless, this slightly truncated protein fails to
anchor b-dystroglycan to the membrane [9]. Additional studies
suggest that low-level expression of this near-full-length dystrophin
enhances muscle function in 3cv mice although it does not reduce
histopathology [8,10]. It is currently unclear whether such
marginal expression can improve the clinical outcome in a severe
DMD model. To address this issue, we crossed the 3cv mutation to
a uko strain in which all utrophin isoforms are eliminated [5]. We
then analyzed the clinical phenotype of the resulting utrophin
knockout 3cv (uko/3cv) mice. Similar to uko/mdx mice, utrophin
expression and full-length dystrophin expression were eliminated
in uko/3cv mice. However, uko/3cv mice expressed a slightly
shortened dystrophin protein at the same level as that of 3cv mice.
Surprisingly, we observed dramatic clinical improvement. Com-
pared to uko/mdx mice, uko/3cv mice showed significantly higher
body weight, better muscle force and longer lifespan. These
findings suggest that marginal level dystrophin expression may
hold clinical significance under certain conditions.
Materials and Methods
Animals
All animal experiments were approved by the Animal Care and
Use Committee of the University of Missouri and were in
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10ScSn-Dmd
mdx/J (mdx), and B6Ros.Cg-Dmd
mdx-3Cv/J (3cv) mice
were purchased from The Jackson Laboratory (Bar Harbor, ME).
The original utrophin heterozygous mdx (utrn
+/2/mdx) breeders
were gifts of Dr. Mark Grady at Washington University [5,11].
Experimental uko/mdx and uko/3cv mice were generated by in
house breeding (Figure 1A and B).
Genotyping
Experimental mice were genotyped for utrophin knockout, 3cv
mutation, and mdx mutation using strain-specific three-primer
PCR protocols as we reported [11,12]. Wild type utrophin yields a
640 bp diagnostic band. The diagnostic utrophin knockout band is
at 450 bp. For 3cv genotyping, the wild type allele yields a 149 bp
band and the mutant allele yields a 131 bp band. For mdx
genotyping, the wild type allele yields a 134 bp band and the
mutant allele yields a 117 bp band.
Western blot
Western blot was performed according to a previously published
protocol [8]. Whole muscle lysate was obtained from freshly
isolated tibialis anterior muscle. Dystrophin was detected with the
Mandra1 antibody (1:100; clone 7A10, IgG1; a gift from Dr.
Glenn Morris, The Robert Jones and Agnes Hunt Orthopaedic
Hospital, UK) [13]. Utrophin was detected with a mouse
monoclonal antibody against utrophin amino acid residues 768-
874 (#610896, 1:250; clone 55, IgG1; BD Biosciences, San Diego,
CA). For the loading control, membrane was probed with an anti-
a-tubulin antibody (1:3,000; clone B-5-1-2; Sigma, St Louis, MO).
The relative level of dystrophin expression was quantified with the
Image J software (version 1.36b). For each blot, dystrophin in
BL10 muscle was arbitrarily defined as 100%.
Immunofluorescence staining
Dystrophin immunofluorescence staining was performed ac-
cording to a published protocol [2,8]. The primary antibody
was Dys-2 (1:30; Vector Laboratories, Burlingame, CA). The
secondary antibody was an Alexa Fluor 594 conjugated F(ab’)2
fragment of goat anti-mouse IgG (H+L) (1:100; Invitrogen,
Carlsbad, CA).
In vitro evaluation of the EDL muscle force
The absolute twitch and tetanic (80, 120, and 150 Hz) forces of
the EDL muscle were measured in vitro at 30uC using a 300B
dual-mode servomotor transducer and a DMC/DMA software
(Aurora Scientific, Inc., Aurora, Ontario, Canada) as we published
before [8,11,14,15]. Muscle cross-sectional area (CSA) was
calculated according to the following equation, CSA = (muscle
mass)/(0.44 x Lo x muscle density). 0.44 represents the ratio of
fiber length to optimal muscle length (Lf/Lo) for the EDL muscle.
Muscle density is 1.06 g/cm
3. The specific force (kN/m
2) was
calculated by normalizing the absolute muscle force with the CSA.
After tetanic force measurement, the muscle was rested for 10 min
and then subjected to five rounds of eccentric contraction injury
according to our previously published protocol [8,11,14,15]. The
percentage of force drop following each round of eccentric
contraction was recorded.
Statistical analysis
Data are presented as mean 6 standard error of mean.
Statistical analysis for body weight and EDL muscle contractility
was performed with the SPSS software (SPSS, Chicago, IL).
Statistical significance was determined by t test. Statistical analysis
for survival was performed with the Prism 4 software (GraphPad,
San Diego, CA). Statistical significance was determined by the
Mantel-Cox log-rank test. The Bonferroni corrected threshold was
used to set the significance level. Difference was considered
significant when P,0.05.
Results
Generation of uko/3cv mice
Experimental uko/mdx mice were generated by crossing
utrophin heterozygous mdx mice (Figure 1A) [5]. Experimental
uko/3cv mice were generated through three rounds of breeding
(Figure 1B). We first generated male utrophin heterozygous 3cv
mice by crossing male utrophin heterozygous mdx mice with
female 3cv mice. We then generated female utrophin heterozygous
3cv mice by crossing male utrophin heterozygous 3cv mice with
female 3cv mice. Finally utrophin heterozygous 3cv mice were
crossed to generate uko/3cv mice (Figure 1B). The genotype of all
experimental mice was verified by PCR (Figure 1C) [11,12].
Figure 1. Generation of uko/mdx and uko/3cv mice. A, Outline of the breeding scheme to generate uko/mdx mice; B, Outline of the breeding
scheme to generate uko/3cv mice. Rectangle, male mice; oval, female mice; white background, pure genetic background; gray background, mixed
genetic background; bolded letters, experimental mice. C, Representative genotyping photomicrographs. Top panel, utrophin PCR. Wild type yields a
640 bp band. Knockout yields a 450 bp band. Heterozygous yields both bands. Middle panel, mdx3cv PCR. Wild type yields a 149 bp band. Mdx3cv
yields a 131 bp band. Bottom panel, mdx PCR. Wild type yields a 134 bp band. Mdx yields a 117 bp band. Heterozygous yields both bands. Utrn +/2,
utrophin heterozygous; Mdx +/2, heterozygous mdx mice; H2O, negative control (without DNA template).
doi:10.1371/journal.pone.0015286.g001
Minimal Dystrophin Expression Improves U-DKO Mice
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e15286Dystrophin and utrophin expression was confirmed by western
blot (Figure 2A). In uko/mdx mice, dystrophin and utrophin were
essentially undetectable (Figure 2A). In uko/3cv mice, utrophin
was completely eliminated while a near-full length dystrophin was
seen at a level comparable to that of 3cv mice (Figure 2A) [7,8].
Marginal level dystrophin expression in 3cv and uko/3cv mice was
further illustrated by immunofluorescence staining (Figure 2B).
Body weight and life span were significantly improved in
uko/3cv mice
At 8 months of age, mdx, 3cv and uko/3cv were essentially
indistinguishable on visual examination (Figure 3A). There was
also no apparent activity deficiency in 8-m-old uko/3cv mice
(Video S1). In contrast, uko/mdx mice appeared clearly emaciated
at 2 months of age (Figure 3B). In age-matched (2.5-m-old) mice,
the body weight of uko/3cv mice was significantly higher than that
of uko/mdx mice irrespective of the gender (Figure 3C).
All uko/mdx mice die within four months after birth [2,4,5,6].
Surprisingly, all uko/3cv mice were alive at this age (Figure 3D).
The median survival age of male and female uko/3cv mice
reached 580 and 553 days, respectively.
The specific force of the uko/3cv EDL muscle significantly
outperformed that of uko/mdx mice
To study the influence of marginal level dystrophin expression
on muscle contractility, we measured the anatomic property,
twitch/tetanic force and eccentric contraction profile of the EDL
muscle in 2.5-m-old male mice. Compared to that of uko/mdx
mice, muscle weight, optimal length and cross-sectional area were
significantly increased in uko/3cv mice (Table 1). Uko/3cv also
showed significantly higher specific twitch and tetanic forces.
Interestingly, both strains showed a similar eccentric contraction
profile (Figure 4).
Discussion
Tremendous progress has been achieved over the last few years
in developing novel pharmacological and genetic therapies for
treating DMD. Many approaches (such as stop codon read-
through and exon skipping) aim at expressing a functional
dystrophin molecule [16,17]. It is unlikely that such attempts will
completely restore dystrophin expression to the wild type level. To
determine whether marginal level dystrophin expression is
clinically relevant, we compared body weight, life span and EDL
muscle contractility between uko/mdx and uko/3cv mice. These
mice carry point mutations in the dystrophin gene and null
mutation of all utrophin genes. As a result, utrophin and full-
length dystrophin expression is abolished.
Uko/mdx mice are well-established clinical DMD models [4,5].
They experience significant growth retardation and die prema-
turely (Figure 3) [2,4,5,6]. 3cv mice expressed a near full-length
dystrophin protein at approximately 5% of the normal level
Figure 2. Dystrophin expression in uko/mdx and uko/3cv mice. A, Left panel, Representative western blots from skeletal muscle of 2.5-m-old
mice. Top two rows show representative dystrophin expression from two independent experiments. The third row shows representative utrophin
expression. a-Tubulin western blot (the bottom row) serves as the loading control. Right panel, Densitometry quantification of dystrophin expression.
N=4 for BL10, N=3 for uko/mdx and N=4 for uko/3cv. B, Representative dystrophin immunofluorescence staining. Dystrophin antibody was not
applied to the slide in the 2nd antibody only photomicrograph.
doi:10.1371/journal.pone.0015286.g002
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(Figure 2). Surprisingly, uko/3cv mice developed a much milder
phenotype. Their body weight was significantly higher at two and
half months of age and their daily activity appeared minimally
impaired at eight months of age (Figure 3C, Video S1). Further,
the EDL muscle of uko/3cv mice showed significantly enhanced
specific twitch and tetanic forces (Figure 4). Remarkably, we
observed a significantly increased life span in uko/3cv mice. The
median survival reached ,1.5 years (Figure 3D). The longest-lived
uko/3cv mouse did not succumb until 22-month-old.
A crucial issue in developing DMD therapy is to determine the
minimal levels of dystrophin needed to mitigate the clinical
manifestation. Previous transgenic studies suggest that dystrophin
expression at 20% of the normal level is sufficient to ameliorate
histological lesions and correct functional deficits in mdx skeletal
muscle [18,19]. We have also demonstrated that ,5% dystrophin
level significantly enhanced muscle force in mdx3cv mice although
it failed to prevent sarcolemmal leakage and muscle necrosis [8].
Recently, a patient with 29% protein level dystrophin expression
was found free of skeletal muscle disease at age 23 [20]. However,
a female carrier who had 45% protein level dystrophin expression
on western blot was found with severe muscular dystrophy [21].
Interestingly, another female carrier with 30% level dystrophin
expression showed a mild phenotype at age 63 [21]. Collectively,
these results suggest that the clinical manifestation of DMD in a
particular subject may be regulated by a number of factors. Our
data here suggest that a threshold level of ,5% dystrophin
expression may meet the basic growth needs and prolong survival
in a phenotypic DMD mouse model.
While the finding is encouraging, we would also like to point out
several important limitations. First, the sample size is relatively
small, especially for the life span study (Figure 3D, N=6 for uko/
3cv male and N=4 for uko/3cv female). Unfortunately this is an
inherent limitation of the study. Compared to other strains of
dystrophin-deficient mice (such as mdx), 3cv mice show signifi-
cantly reduced fertility due to abnormal spermatozoa [22]. We
have also experienced great difficulties in the breeding. Neverthe-
less, all our uko/3cv mice outlived uko/mdx mice.
Second, uko/mdx mice were on the BL10 background [11].
However, uko/3cv mice were on a mixed genetic background of
BL10 and C57Bl/6. It is possible the difference in the genetic
background of the mouse strain may have also influenced the results.
As a matter of fact, a series of recent publications have clearly
demonstrated the dramatic leverage of various genetic modifiers on
the dystrophic phenotype [23,24,25,26]. Although not proved yet,
variations in the dystrophin level and disease severity seen in DMD
patients may also relate to the genetic modifiers [20,21].
Third, Rafael et al. have previously reported an uko/3cv strain
based on a different uko model [4]. Interestingly, their uko/3cv strain
developed the same clinical phenotype as uko/mdx mice and none
lived beyond 20 weeks of age [27]. This outcome is completely
different from our observation (Figure 3). The exact reason of the
discrepancy is currently not clear. One possibility may relate to the
uko model used in the study. All utrophin isoforms are eliminated in
the uko model we used [5]. However, expression of the smaller
utrophin isoforms is not abolished in the uko strain used by Rafael et
al [4]. Rafael et al indeed observed an up-regulation of 113 kD G-
utrophin in the kidney in their uko/3cv mice [27,28]. Forced
expression of smaller dystrophin isoforms (such as Dp71 and Dp116)
has been shown to worsen muscle disease of dystrophin-null mice by
competing with up-regulated utrophin [29,30,31]. Future studies are
needed to determine whether up-regulated smaller utrophin isoforms
compete away the near-full length dystrophin protein from the
sarcolemma in uko/3cv mice reported by Rafael et al.
Fourth, it should also be pointed out that our observation might
relate to low-level D65/66 dystrophin expression during the
embryonic stage. Several studies suggest that dystrophin deficiency
causes fetal developmental abnormalities [32,33,34]. If this is the
case, then the therapeutic implication of restoring low-level
dystrophin expression later in life will be limited.
An interesting finding of the study is the seemingly different
impact on the life span between male and female mice (Figure 3D).
The median survival age of male uko/3cv mice was slightly longer
than that of female. Male mice also appeared to die over a greater
Figure 3. Body weight and survival of uko/mdx and uko/3cv
mice. A, Representative photomicrographs of 8-m-old male mdx,
mdx3cv and uko/3cv mice. B, Representative photomicrographs of 2-
m-old male mdx and uko/mdx mice. C, Body weight of 2.5-m-old uko/
mdx (N=11 for male and N=9 for female) and aged-matched uko/3cv
(N=6 for male and N=3 for female) mice. Asterisk, significantly
different from the other group (p,0.02). D, Kaplan–Meier survival
curves for uko/mdx (N=5 for male and N=6 for female) and uko/3cv
(N=6 for male and N=4 for female) mice.
doi:10.1371/journal.pone.0015286.g003
Table 1. Anatomic features of the EDL muscle in 2.5-m-old
mice.
Strain N Weight (mg) Lo (mm) CSA (mm
2)
uko/mdx 8 6.3960.99 10.6760.53 1.2460.14
uko/3cv 6 9.5260.31 12.5160.17 1.6460.07
p value 0.021 0.013 0.04
doi:10.1371/journal.pone.0015286.t001
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to the small sample size of the current study. Future investigation
with a larger sample size will help resolve the discrepancy.
Nevertheless, it is worth to point out that gender may indeed play
a role in dystrophin-deficient mice. A recent study by Bostick et al
suggests that female mdx mice develop much severe cardiomyop-
athy than age-matched males [35].
In summary, we have demonstrated that minimal level
dystrophin expression resulted in significant clinical improvement
in a symptomatic mouse DMD model. Interestingly, a recent
clinical trial with the read-through drug gentamicin also revealed a
significant drop of the serum creatine kinase level despite only a
marginal increase of dystrophin expression. Together, these results
suggest that low-level dystrophin expression may still offer some
clinical benefits for certain DMD patients [36].
Supporting Information
Figure S1 Schematic outline of RNA expression in
mdx3cv mice. A, Normal transcription/splicing yields an in-
frame full-length transcript. B to D, Alternative transcripts in
mdx3cv muscle. Only D65/66 transcript is in-frame. Red letter
marks the mutation. (Note, this figure is based on the results
published by Cox et al Nature Genetics 4:87-93, 1993).
(TIF)
Video S1 8-m-old mdx, mdx3cv and uko/3cv male mice
show similar activity. The strain is marked by color tape on
the tail. Gray, mdx; green, mdx3cv; red, uko/3cv.
(MPG)
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